Mobius Therapeutics, LLC
The only FDA approved formulation of mitomycin-c with an ophthalmic indication. Orphan drug status. Patent exclusivity until 2029.
- Stage $1M in TTM Revenue
- Industry Biotechnology
- Location St. Louis, MO, USA
- Currency USD
- Founded April 2006
- Employees 9
- Incorporation Type LLC
- Website mobiustherapeutics.com
Company Summary
Mobius has developed a patent protected system, Mitosol®, for delivering mitomycin-c in glaucoma, refractive, and pterygium surgeries. Mobius gained FDA approval in 2012 for glaucoma and is pursuing additional indications. Mitosol® enhances OR safety and is stored at room temperature; shelf life grows from 14 days to 2 years vs compounding. Potency is assured and technique is unchanged. Mitosol is reimbursed whereas compounded MMC is not.
Team
-
Edward Jerome TimmPresident and CEO 25 years’ in the medical/surgical device industry
Founded or led franchises for multiple companies:
American Hospital Supply Corp; Applied Medical Resources Corporation; Storz Ophthalmics; and Given Imaging.
Responsible for Commercial Development at Synergetics, Inc.
Took from startup to IPO, operating in sixty countries and two disciplines
BA, Philosophy, University of Dayton
11 issued US patents, with numerous patents pending -
Mark W. WrightChief Financial Officer Finance executive with significant experience in venture capital backed, rapid growth, life science, and technology companies
Served as a CFO and board member of several companies, including:
BrainScope Company, Inc.; Everest Biomedical I n s t r u m e n t s Company; Abiliti Solutions, Inc.; and Technology Applications, Inc.
Certified Public Accountant
BSBA from Saint Louis University
Advisors
-
Thompson CoburnLawyerUnconfirmed
Rubin BrownAccountantUnconfirmed
Previous Investors
-
BiogeneratorUnconfirmed
PrivateUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.